Gilead tries new triple-target T-cell engagers in $1.5B-plus Merus collab

Bispecific T-cell engagers are just now stepping into the oncology spotlight, but that’s not stopping one pharma company from investigating the next frontier of the modality.

Gilead and Merus have inked a partnership worth more than $1.5 billion to discover trispecific T-cell engagers, the companies announced Wednesday.